CHMA stock forecast
Our latest prediction for Chiasma, Inc.'s stock price was made on the Dec. 20, 2018 when the stock price was at 2.37$.
In the short term (2weeks), CHMA's stock price should outperform the market by 7.48%. During that period the price should oscillate between -8.61% and +20.90%.
In the medium term (3months), CHMA's stock price should outperform the market by 7.08%. During that period the price should oscillate between -18.96% and +50.31%.Get email alerts
About Chiasma, Inc.
Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.23$ per share.
The book value per share is 1.98$
Three months stock forecastDec. 20, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|